ScholarLens Back to search
2011•Expert Review of Anti-infective TherapyOpen access

Panton–Valentine leukocidin antibodies for the treatment of MRSA skin infections?

Michaël Otto

Open full text 4 citations

Abstract

Evaluation of: Hermos CR, Yoong P, Pier GB. High levels of antibody to Panton–Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis. 51(10), 1138–1146 (2010).Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton–Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA.

About this research paper

What this paper is about

Evaluation of: Hermos CR, Yoong P, Pier GB. High levels of antibody to Panton–Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis. 51(10), 1138–1146 (2010).Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton–Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA.

Why it matters

OpenAlex reports 4 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Evaluation of: Hermos CR, Yoong P, Pier GB. High levels of antibody to Panton–Valentine leukocidin are not associated with resistance to Staphylococcus aureus-associated skin and soft-tissue infection. Clin. Infect. Dis. 51(10), 1138–1146 (2010).Methicillin-resistant Staphylococcus aureus (MRSA) has recently caused epidemic outbreaks of community-associated (CA) skin infections. The infecting strains frequently contain the genes encoding the staphylococcal toxin, Panton–Valentine leukocidin (PVL). On that ground, the use of PVL-based vaccines has been proposed for the treatment of CA-MRSA infections, despite experimental and epidemiological evidence that does not support a major role of the PVL toxin in CA-MRSA skin disease. Hermos et al. show that antibodies to PVL do not protect from CA-MRSA skin infections in children, strongly suggesting that PVL-based immunization is of little benefit for this most frequent disease caused by CA-MRSA.

Key concepts: Leukocidin, Panton–Valentine leukocidin, Staphylococcus aureus, Staphylococcal Skin Infections, Microbiology, Outbreak, Antibody, Skin infection

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Panton–Valentine leukocidin antibodies for the treatment of MRSA skin infections? — Research Paper | ScholarLens